Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report) was down 4% on Thursday . The stock traded as low as $1.3801 and last traded at $1.43. 1,447,315 shares traded hands during trading, a decline of 5% from the average daily volume of 1,521,488 shares. The stock had previously closed at $1.49.
Qualigen Therapeutics Price Performance
The firm has a 50-day simple moving average of $1.35 and a 200 day simple moving average of $1.67. The stock has a market capitalization of $2.42 million, a P/E ratio of -0.19 and a beta of 0.24.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.
Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories.
Featured Articles
- Five stocks we like better than Qualigen Therapeutics
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
